CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
17/02/2026 21:24
Removes incorrect reference to a kidney disease treatment deal from the headline Feb 18 (Reuters) - Australia's CSL CSL.AX said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co LLY.N, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease. (Reporting by Shivangi Lahiri in Bengaluru; Editing by Maju Samuel) ((Shivangi.Lahiri@thomsonreuters.com;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX